Gerresheimer cuts 2026 outlook citing project delays, production expansion costs

June 29 (Reuters) - German medical packaging firm Gerresheimer cut its margin outlook for 2026, saying project delays and operational issues including production ramp-ups weighed on earnings.

In a separate statement, the Duesseldorf-based company said its revenue in the 2025 financial year came at €2.3 billion ($2.62 billion), broadly in line with an LSEG poll of analysts, but it said it will not pay a dividend for the period.

Its shares fell almost 10% following the announcement but recovered some losses and were down 3% by 1053 GMT, after losing almost 15% of their value since the beginning of the year.

Gerresheimer now expects an adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) margin of around 17% to 18% for the current year before M&A and refinancing activities, down from a previous forecast of 18% to 19%.

Gerresheimer also anticipates negative free cash flow of between €-50 million and €-100 million.

($1 = 0.8772 euros)

(Reporting by Danny Callaghan and Paolo Laudani in Gdansk; Editing by Susan Fenton)